UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Clinical and translational science, 2021-09, Vol.14 (5), p.1756-1768

2021

Volltextzugriff (PDF)

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Critical care medicine, 2001-04, Vol.29 (4), p.765-769

2001

Volltextzugriff (PDF)

Relationship Between Interleukin-6 Plasma Concentration in Patients with Sepsis, Monocyte Phenotype, Monocyte Phagocytic Properties, and Cytokine Production

Clinical infectious diseases, 2000-12, Vol.31 (6), p.1338-1342

2000

Volltextzugriff (PDF)

Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions

European journal of pharmaceutical sciences, 2022-05, Vol.172, p.106155-106155, Article 106155

2022

Volltextzugriff (PDF)

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

The New England journal of medicine, 2011-10, Vol.365 (17), p.1586-1596

2011

Volltextzugriff (PDF)

A Simple Way for Implementing Extraction Columns of Infinite Height in Flowsheet Simulators

Chemie ingenieur technik, 2019-03, Vol.91 (3), p.314-322

2019

Volltextzugriff (PDF)

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Annals of the rheumatic diseases, 2024-03, Vol.83 (3), p.360-371

2024

Volltextzugriff (PDF)

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Critical care medicine, 2004-11, Vol.32 (11), p.2173-2182

2004

Volltextzugriff (PDF)

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis

Dermatology (Basel), 2008-03, Vol.216 (3), p.260-270

2008

Volltextzugriff (PDF)

Briakinumab versus Methotrexate for Psoriasis

The New England journal of medicine, 2012-01, Vol.366 (4), p.379-380

2012

Volltextzugriff (PDF)

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

Modern rheumatology, 2008-06, Vol.18 (3), p.252-262

Miyasaka, Nobuyuki

2008

Volltextzugriff (PDF)

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study

Critical care medicine, 1996-05, Vol.24 (5), p.733-742

1996

Volltextzugriff (PDF)

Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines

Critical care medicine, 2000-06, Vol.28 (6), p.1854-1860

2000

Volltextzugriff (PDF)

TNF-NEUTRALISATION, IN SEPSIS GUIDED BY IL-6 SERUM LEVELS: 300

Shock (Augusta, Ga.), 1997-03, Vol.7 Suppl, p.76-76

Kaul, Martin

1997

Volltextzugriff (PDF)

TNF-NEUTRALISATION, IN SEPSIS GUIDED BY IL-6 SERUM LEVELS: 300

Shock (Augusta, Ga.), 1997-03, Vol.7 (Supplement), p.76

Kaul, Martin

1997

Volltextzugriff (PDF)

MONARCS: Statistical or Clinical Meaning?

Critical care medicine, 2005-09, Vol.33 (9), p.2144-2146

2005

Volltextzugriff (PDF)

MONARCS: Statistical or Clinical Meaning?

Critical care medicine, 2005-09, Vol.33 (9), p.2144-2144

Jaimes, Fabián A

2005

Volltextzugriff (PDF)

A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer

Cancer, 1991-10, Vol.68 (7), p.1507-1512

1991

Volltextzugriff (PDF)

Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels

Shock (Augusta, Ga.), 1994-04, Vol.1 (4), p.237-245

1994

Volltextzugriff (PDF)

Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies

Shock (Augusta, Ga.), 1996-10, Vol.6 (4), p.233-237

1996

Volltextzugriff (PDF)

HEMOSTATIC PARAMETERS IN SEPSIS PATIENTS TREATED WITH ANTI-TNF±-MONOCLONAL ANTIBODIES

Shock (Augusta, Ga.), 1996-10, Vol.6 (4), p.233-237

1996

Volltextzugriff (PDF)

Changes in skeletal muscle pO2 after administration of anti-TNF alpha-antibody in patients with severe sepsis: comparison to interleukin-6 serum levels, APACHE II, and Elebute scores

Shock (Augusta, Ga.), 1994-04, Vol.1 (4), p.246-253

1994

Volltextzugriff (PDF)

Effector mechanisms in myasthenia gravis: End-plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules

Muscle & nerve, 1986-05, Vol.9 (4), p.306-312

1986

Volltextzugriff (PDF)

Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial

Psoriasis forum, 2007-06, Vol.13a (1), p.4-11

2007

Volltextzugriff (PDF)

1 – 25 von 340

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(291)
Mit Volltextzugriff
(293)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(331)
Japanisch
(36)
Deutsch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(201)
Life Sciences & Biomedicine
(168)
Humans
(143)
Female
(85)
Male
(82)
Adult
(67)
Middle Aged
(61)
Biological And Medical Sciences
(48)
Medical Sciences
(39)
Oncology
(23)
Infectious Diseases
(22)
Human Immunodeficiency Virus
(21)
Neurosciences & Neurology
(21)
Aged
(20)
General & Internal Medicine
(20)
Hiv
(20)
Immunology
(19)
Neurosciences
(19)
Risk Factors
(18)
Science & Technology - Other Topics
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(12)
Critical Care Medicine
(7)
Acta Paediatrica
(6)
Shock
(6)
Blood
(5)
Chest
(5)
Plants
(5)
Ssrn Electronic Journal
(5)
The New England Journal Of Medicine
(5)
Acta Paediatrica, International Journal Of Paediatrics
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Relationship Between Interleukin-6 Plasma Concentration in Patients with Sepsis, Monocyte Phenotype, Monocyte Phagocytic Properties, and Cytokine Production

Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

A Simple Way for Implementing Extraction Columns of Infinite Height in Flowsheet Simulators

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis

Briakinumab versus Methotrexate for Psoriasis

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study

Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines

TNF-NEUTRALISATION, IN SEPSIS GUIDED BY IL-6 SERUM LEVELS: 300

TNF-NEUTRALISATION, IN SEPSIS GUIDED BY IL-6 SERUM LEVELS: 300

MONARCS: Statistical or Clinical Meaning?

MONARCS: Statistical or Clinical Meaning?

A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer

Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels

Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies

HEMOSTATIC PARAMETERS IN SEPSIS PATIENTS TREATED WITH ANTI-TNF±-MONOCLONAL ANTIBODIES

Changes in skeletal muscle pO2 after administration of anti-TNF alpha-antibody in patients with severe sepsis: comparison to interleukin-6 serum levels, APACHE II, and Elebute scores

Effector mechanisms in myasthenia gravis: End-plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules

Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial

Suchergebnisse filtern